CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) plus rucaparib   for post-chemotherapy (CT) metastatic castration-resistant prostate   cancer (mCRPC).

Document type:: Meeting Abstract
Author(s):: Pachynski, Russell Kent; Retz, Margitta; Goh, Jeffrey C.; Burotto, Mauricio; Gravis, Gwenaelle; Castellano, Daniel; Flechon, Aude; Zschaebitz, Stefanie; Shaffer, David R.; Limon, Juan Carlos Vazquez; Grimm, Marc-Oliver; McCune, Steven L.; Amin, Neha P.; Li, Jia; Wang, Xuya; Unsal-Kacmaz, Keziban; Saad, Fred; Petrylak, Daniel P.; Fizazi, Karim
Title:: CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) plus rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).
Journal title abbreviation:: J Clin Oncol
Year:: 2021
Journal volume:: 39 Suppl S
Journal issue:: 15
Fulltext / DOI:: doi:10.1200/JCO.2021.39.15_suppl.5044
Print-ISSN:: 0732-183X
TUM Institution:: Urologische Klinik und Poliklinik
BibTeX

Occurrences: